Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer

Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis

(2018) Shuhei Enjoji et al.   MOLECULAR CANCER RESEARCH

SET Oncogene is Upregulated in Pediatric Acute Lymphoblastic Leukemia

(2018) Sema Sirma Ekmekci et al.   TUMORI

OP449 inhibits breast cancer growth without adverse metabolic effects

(2017) Gadi Shlomai et al.   ENDOCRINE-RELATED CANCER

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

(2017) Man-Hsin Hung et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Using the MCoTI-II Cyclotide Scaffold To Design a Stable Cyclic Peptide Antagonist of SET, a Protein Overexpressed in Human Cancer

(2016) Charlotte D’Souza et al.   BIOCHEMISTRY

Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review

(2016) Ion Cristóbal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential

(2016) M-H Hung et al.   ONCOGENE

Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer

(2016) Ion Cristóbal et al.   Oncotarget

SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A

(2015) Man-Hsin Hung et al.   Oncotarget

Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation

(2014) Ion Cristóbal et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer

(2014) I Cristóbal et al.   BRITISH JOURNAL OF CANCER

Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer

(2014) I. Cristobal et al.   CLINICAL CANCER RESEARCH

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

(2014) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer

(2014) Amy S. Farrell et al.   MOLECULAR CANCER RESEARCH

PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential

(2014) I. Cristobal et al.   MOLECULAR CANCER THERAPEUTICS

Protein phosphatase 2A is essential to maintain active Wnt signaling and its Aβ tumor suppressor subunit is not expressed in colon cancer cells

(2014) M. Carmen Figueroa-Aldariz et al.   MOLECULAR CARCINOGENESIS

Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer

(2014) LEI DONG et al.   Oncology Letters

Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment

(2013) Archana Mukhopadhyay et al.   CANCER BIOLOGY & THERAPY

Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways

(2012) Clara Lemos et al.   CURRENT PHARMACEUTICAL DESIGN

SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification

(2012) Andréia M. Leopoldino et al.   ORAL ONCOLOGY

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

(2011) D. J. Christensen et al.   BLOOD

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

(2011) I. Cristobal et al.   HAEMATOLOGICA

Inhibition of p53 acetylation by INHAT subunit SET/TAF-Iβ represses p53 activity

(2011) Ji-Young Kim et al.   NUCLEIC ACIDS RESEARCH

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

(2011) C H Switzer et al.   ONCOGENE

Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells

(2010) Kyoung Bin Cho et al.   CANCER LETTERS

Adjuvant colon cancer chemotherapy: where we are and where we'll go

(2010) L. Lombardi et al.   CANCER TREATMENT REVIEWS

I2PP2A regulates p53 and Akt correlatively and leads the neurons to abort apoptosis

(2010) Gong-Ping Liu et al.   NEUROBIOLOGY OF AGING

Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma

(2009) Angel Chao et al.   CANCER LETTERS

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE